Literature DB >> 15099314

Efficacy of sclerotherapy in varicose veins-- prospective, blinded, placebo-controlled study.

Birgit Kahle1, Katharina Leng.   

Abstract

OBJECTIVE: The objective of this study was to investigate the efficacy of sclerotherapy for varicose veins in a randomized blinded study.
METHODS: Twenty-five patients with varicose veins (C(2-4), E(P), A(SP), P(R)) were included. Fourteen subjects received polidocanol (Aethoxysklerol) and 11 patients received normal saline injections. Compression was applied for 1 week. One, 4, and 12 weeks later controls were performed using duplex ultrasonography. The quotient of venous by arterial volume flow was used as quantitative hemodynamic pattern. Patients and the examiner were unaware of which liquid had been injected.
RESULTS: In comparison to group 2, 76.8% of the veins treated with polidocanol were completely occluded (p<0.0001). In group 1 the venoarterial flow index decreased from 1.45+/-0.66 to 1.06+/-0.2 (p=0.05). In 11 occluded veins of 14 (group 1), the venoarterial flow index decreased from 1.5+/-0.07 to 0.98+/-0.12 (p<0.05), which is a level found in competent veins. In group 2, the venoarterial flow index remained stable increased.
CONCLUSIONS: Injection sclerotherapy using polidocanol (Aethoxysklerol) is efficient to obliterate varicose veins and to improve venous hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099314     DOI: 10.1111/j.1524-4725.2004.30207.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

Review 1.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 2.  [Guidelines for sclerotherapy of varicose veins : S2k guideline of the German Society of Phlebology (DGP) in cooperation with the following professional associations: DDG, DGA, DDG, BVP. German Version].

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

Review 3.  Injection sclerotherapy for varicose veins.

Authors:  Ricardo de Ávila Oliveira; Rachel Riera; Vladimir Vasconcelos; Jose Cc Baptista-Silva
Journal:  Cochrane Database Syst Rev       Date:  2021-12-10

Review 4.  S2k guidelines: diagnosis and treatment of varicose veins.

Authors:  F Pannier; T Noppeney; J Alm; F X Breu; G Bruning; I Flessenkämper; H Gerlach; K Hartmann; B Kahle; H Kluess; E Mendoza; D Mühlberger; A Mumme; H Nüllen; K Rass; S Reich-Schupke; D Stenger; M Stücker; C G Schmedt; T Schwarz; J Tesmann; J Teßarek; S Werth; E Valesky
Journal:  Hautarzt       Date:  2022-04-19       Impact factor: 1.198

5.  Endovascular laser treatment of incompetent saphenous veins using the 1470 nm diode laser and radial fiber.

Authors:  Georgios Vourliotakis; Georgios Sahsamanis; Paschalis Evagelidis; Christina Aivatidi
Journal:  Ann Med Surg (Lond)       Date:  2017-12-07

Review 6.  Sclerotherapy in the treatment of varicose veins : S2k guideline of the Deutsche Gesellschaft für Phlebologie (DGP) in cooperation with the following societies: DDG, DGA, DGG, BVP.

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-12       Impact factor: 0.751

7.  Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Vessel Plus       Date:  2021-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.